公开(公告)号：US20160129115A1

公开(公告)日：2016-05-12

申请号：US14745276

申请日：2015-06-19

Applicant: LFB USA, Inc.

Inventor： Gerald R. Magneson ,  Greg J. Allard ,  Nicholas C. Masiello ,  Usha S. Patel ,  Lauren K. Fontana ,  Joseph L. Pearce ,  Jerry A. Grandoni

IPC: A61K47/26 ,  A61K47/12 ,  A61K47/02 ,  A61K38/57

CPC classification number: A61K47/26 ,  A61K9/0019 ,  A61K38/4833 ,  A61K38/57 ,  A61K47/02 ,  A61K47/12

Abstract: In one aspect, the invention provides liquid stable formulations of antithrombin.

Abstract translation: 一方面，本发明提供了抗凝血酶的液体稳定制剂。

公开(公告)号：US20200255518A1

公开(公告)日：2020-08-13

申请号：US16798047

申请日：2020-02-21

Applicant: LFB USA, Inc. ,  Genzyme Corporation

Inventor： Daniel Schindler ,  Harry M. Meade ,  Timothy Edmunds ,  John McPherson

IPC: C07K16/28 ,  C07K16/04

Abstract: The invention relates, in part, to antibodies with increased ADCC activity. Methods of producing such antibodies are also provided. The antibodies of the invention are produced in mammary epithelial cells, such as those in a non-human transgenic animal engineered to express and secrete the antibody in its milk. The antibodies or compositions comprising the antibodies can be used to treat disease in which ADCC activity provides a benefit. In one embodiment, therefore, the antibodies or compositions comprising the antibodies can be used to treat cancer, lymphoproliferative disease or autoimmune disease.

公开(公告)号：US20160326547A1

公开(公告)日：2016-11-10

申请号：US15108061

申请日：2014-12-19

Applicant: LFB USA, INC.

Inventor： Harry M. Meade ,  William G. Gavin

IPC: C12N15/85 ,  C12P19/26 ,  A01K67/027 ,  A61K31/727

CPC classification number: C12N15/8509 ,  A01K67/0275 ,  A01K2217/15 ,  A01K2227/101 ,  A01K2227/102 ,  A01K2267/02 ,  A61K31/727 ,  C12N2015/8518 ,  C12P19/26

Abstract: The disclosure provides methods, cells and transgenic non human mammals for the production of heparin. Specifically, the method comprising providing a transgenic non human mammal or mammary epithelial cells modified to express one or more heparin biosynthesis enzymes, and harvesting heparin produced. Further provided are the cells and transgenic non human mammals thereof as well as the heparin obtained from these cells or transgenic non human mammals.

Abstract translation: 本公开提供了用于生产肝素的方法，细胞和转基因非人哺乳动物。 具体地说，该方法包括提供被修饰以表达一种或多种肝素生物合成酶的转基因非人哺乳动物或乳腺上皮细胞，以及收获产生的肝素。 还提供了细胞和其转基因非人哺乳动物以及从这些细胞或转基因非人哺乳动物获得的肝素。

公开(公告)号：US20160039913A1

公开(公告)日：2016-02-11

申请号：US14427117

申请日：2013-09-10

Applicant: LFB USA, INC. ,  BETH ISRAEL DEACONESS MEDICAL CENTER, INC.

Inventor： Harry M. MEADE ,  Lisa CAVACINI

IPC: C07K16/10

CPC classification number: C07K16/1045 ,  A61K2039/505 ,  A61K2039/542 ,  A61K2039/55 ,  C07K16/1063 ,  C07K2317/12 ,  C07K2317/52 ,  C07K2317/76

Abstract: In one aspect, the disclosure provides methods of treating HIV and decreasing the chance of HIV infection in a subject, and compositions used in these methods.

Abstract translation: 一方面，本公开提供了治疗HIV并降低受试者中HIV感染机会的方法，以及用于这些方法的组合物。